-
Something wrong with this record ?
Revaskularizace nemá u pacientů se stenózou renální tepny příznivý vliv na kontrolu krevního tlaku, renální funkci ani kardiovaskulární prognózu
[Revascularization versus medical therapy for renal-artery stenosis]
Language Czech Country Czech Republic
Document type Comparative Study, Multicenter Study
- MeSH
- Antihypertensive Agents therapeutic use MeSH
- Angioplasty, Balloon adverse effects MeSH
- Adult MeSH
- Financing, Organized MeSH
- Platelet Aggregation Inhibitors therapeutic use MeSH
- Kaplan-Meier Estimate MeSH
- Drug Therapy, Combination MeSH
- Combined Modality Therapy MeSH
- Blood Pressure MeSH
- Middle Aged MeSH
- Humans MeSH
- Renal Artery Obstruction MeSH
- Randomized Controlled Trials as Topic MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Multicenter Study MeSH
- Comparative Study MeSH
Percutaneous revascularization of the renal arteries improves patency in atherosclerotic renovascular disease, yet evidence of a clinical benefit is limited. METHODS: In a randomized, unblinded trial, we assigned 806 patients with atherosclerotic renovascular disease either to undergo revascularization in addition to receiving medical therapy or to receive medical therapy alone. The primary outcome was renal function, as measured by the reciprocal of the serum creatinine level (a measure that has a linear relationship with creatinine clearance). Secondary outcomes were blood pressure, the time to renal and major cardiovascular events, and mortality. The median follow-up was 34 months. RESULTS: During a 5-year period, the rate of progression of renal impairment (as shown by the slope of the reciprocal of the serum creatinine level) was -0.07x10(-3) liters per micromole per year in the revascularization group, as compared with -0.13x10(-3) liters per micromole per year in the medical-therapy group, a difference favoring revascularization of 0.06x10(-3) liters per micromole per year (95% confidence interval [CI], -0.002 to 0.13; P=0.06). Over the same time, the mean serum creatinine level was 1.6 micromol per liter (95% CI, -8.4 to 5.2 [0.02 mg per deciliter; 95% CI, -0.10 to 0.06]) lower in the revascularization group than in the medical-therapy group. There was no significant between-group difference in systolic blood pressure; the decrease in diastolic blood pressure was smaller in the revascularization group than in the medical-therapy group. The two study groups had similar rates of renal events (hazard ratio in the revascularization group, 0.97; 95% CI, 0.67 to 1.40; P=0.88), major cardiovascular events (hazard ratio, 0.94; 95% CI, 0.75 to 1.19; P=0.61), and death (hazard ratio, 0.90; 95% CI, 0.69 to 1.18; P=0.46). Serious complications associated with revascularization occurred in 23 patients, including 2 deaths and 3 amputations of toes or limbs. CONCLUSIONS: We found substantial risks but no evidence of a worthwhile clinical benefit from revascularization in patients with atherosclerotic renovascular disease. (Current Controlled Trials number, ISRCTN59586944.) 2009 Massachusetts Medical Society
Revascularization versus medical therapy for renal-artery stenosis
The ASTRAL Investigators
- 000
- 00000naa 2200000 a 4500
- 001
- bmc10004694
- 003
- CZ-PrNML
- 005
- 20111210160525.0
- 008
- 100224s2009 xr e cze||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a cze $b eng
- 044 __
- $a xr
- 245 10
- $a Revaskularizace nemá u pacientů se stenózou renální tepny příznivý vliv na kontrolu krevního tlaku, renální funkci ani kardiovaskulární prognózu.
- 246 11
- $a Revascularization versus medical therapy for renal-artery stenosis
- 500 __
- $a The ASTRAL Investigators
- 520 9_
- $a Percutaneous revascularization of the renal arteries improves patency in atherosclerotic renovascular disease, yet evidence of a clinical benefit is limited. METHODS: In a randomized, unblinded trial, we assigned 806 patients with atherosclerotic renovascular disease either to undergo revascularization in addition to receiving medical therapy or to receive medical therapy alone. The primary outcome was renal function, as measured by the reciprocal of the serum creatinine level (a measure that has a linear relationship with creatinine clearance). Secondary outcomes were blood pressure, the time to renal and major cardiovascular events, and mortality. The median follow-up was 34 months. RESULTS: During a 5-year period, the rate of progression of renal impairment (as shown by the slope of the reciprocal of the serum creatinine level) was -0.07x10(-3) liters per micromole per year in the revascularization group, as compared with -0.13x10(-3) liters per micromole per year in the medical-therapy group, a difference favoring revascularization of 0.06x10(-3) liters per micromole per year (95% confidence interval [CI], -0.002 to 0.13; P=0.06). Over the same time, the mean serum creatinine level was 1.6 micromol per liter (95% CI, -8.4 to 5.2 [0.02 mg per deciliter; 95% CI, -0.10 to 0.06]) lower in the revascularization group than in the medical-therapy group. There was no significant between-group difference in systolic blood pressure; the decrease in diastolic blood pressure was smaller in the revascularization group than in the medical-therapy group. The two study groups had similar rates of renal events (hazard ratio in the revascularization group, 0.97; 95% CI, 0.67 to 1.40; P=0.88), major cardiovascular events (hazard ratio, 0.94; 95% CI, 0.75 to 1.19; P=0.61), and death (hazard ratio, 0.90; 95% CI, 0.69 to 1.18; P=0.46). Serious complications associated with revascularization occurred in 23 patients, including 2 deaths and 3 amputations of toes or limbs. CONCLUSIONS: We found substantial risks but no evidence of a worthwhile clinical benefit from revascularization in patients with atherosclerotic renovascular disease. (Current Controlled Trials number, ISRCTN59586944.) 2009 Massachusetts Medical Society
- 650 _2
- $a randomizované kontrolované studie jako téma $7 D016032
- 650 _2
- $a financování organizované $7 D005381
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a balónková angioplastika $x škodlivé účinky $7 D000800
- 650 _2
- $a antihypertenziva $x terapeutické užití $7 D000959
- 650 _2
- $a krevní tlak $7 D001794
- 650 _2
- $a kombinovaná terapie $7 D003131
- 650 _2
- $a kombinovaná farmakoterapie $7 D004359
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a statiny $x terapeutické užití $7 D019161
- 650 _2
- $a Kaplanův-Meierův odhad $7 D053208
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a inhibitory agregace trombocytů $x terapeutické užití $7 D010975
- 650 _2
- $a obstrukce renální arterie $7 D012078
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a multicentrická studie $7 D016448
- 773 0_
- $w MED00012709 $t Postgraduální nefrologie $g Roč. 7, č. 6 (2009), s. 91-92 $x 1214-178X
- 787 18
- $w bmc10004695 $i Recenze v: $t Komentář [k článku Revaskularizace nemá u pacientů se stenózou renální tepny příznivý vliv na kontrolu krevního tlaku, renální funkci ani kardiovaskulární prognózu]
- 856 41
- $u https://www.postgradualninefrologie.cz/download/format/pdf/id/180/ $y plný text volně přístupný
- 910 __
- $a ABA008 $b B 2318 $c 893 $y 8
- 990 __
- $a 20100223151344 $b ABA008
- 991 __
- $a 20100503101442 $b ABA008
- 999 __
- $a ok $b bmc $g 714116 $s 577064
- BAS __
- $a 3
- BMC __
- $a 2009 $b 7 $c 6 $d 91-92 $i 1214-178X $m Postgraduální nefrologie $x MED00012709
- LZP __
- $a 2010-03/mkme